Methyl-15,16-dideutero-linoleat | 134484-38-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Methyl-15,16-dideutero-linoleat
• 英文别名: (9Z,12Z)-12,13-dideuterio-octadeca-9,12-dienoic acid methyl ester；methyl (9Z,12Z)-12,13-dideuteriooctadeca-9,12-dienoate
• CAS: 134484-38-1
• 化学式: C₁₉H₃₄O₂
• 分子量: 296.462
• InChiKey: WTTJVINHCBCLGX-MAYSQPCRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  21
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• OPTIC NEUROPATHY TREATMENT AND REDUCTION OF STEROID- INDUCED OXIDATIVE STRESS WITH STABILIZED POLYUNSATURATED SUBSTANCES
  申请人：Retrotope, Inc.

  公开号：EP3943081A1

  公开（公告）日：2022-01-26

  Some aspects of the invention provide for a method of treating a patient having glaucoma, a non-hereditary optic neuropathy, steroid-induced oxidative stress, or steroid-induced oxidation-related disorders, comprising identifying a patient having a non-hereditary optic neuropathy or steroid-induced oxidative stress or steroid-induced oxidation-related disorders and in need of treatment; repeatedly administering a polyunsaturated substance to the patient or the patient's tissue, wherein the polyunsaturated substance is chemically modified such that one or more bonds is stabilized against oxidation; wherein following said administration, the polyunsaturated substance or a polyunsaturated metabolite thereof comprising said one or more chemical modifications is incorporated into the patient's body or the patient's tissue.

  本发明的某些方面提供了一种治疗患有青光眼、非遗传性视神经病变、类固醇诱导的氧化应激或类固醇诱导的氧化相关紊乱的患者的方法，包括识别患有非遗传性视神经病变或类固醇诱导的氧化应激或类固醇诱导的氧化相关紊乱并需要治疗的患者；向患者或患者的组织重复施用多不饱和物质，其中多不饱和物质经过化学修饰，从而使一个或多个键被稳定以防氧化；其中在所述施用之后，多不饱和物质或其包含所述一个或多个化学修饰的多不饱和代谢物被纳入患者的身体或患者的组织中。
• OPTIC NEUROPATHY TREATMENT AND REDUCTION OF STEROID-INDUCED OXIDATIVE STRESS WITH STABILIZED POLYUNSATURATED SUBSTANCES
  申请人：Retrotope, Inc.

  公开号：EP3116313A2

  公开（公告）日：2017-01-18
• [EN] OPTIC NEUROPATHY TREATMENT AND REDUCTION OF STEROID-INDUCED OXIDATIVE STRESS WITH STABILIZED POLYUNSATURATED SUBSTANCES<br/>[FR] TRAITEMENT DE LA NEUROPATHIE OPTIQUE ET RÉDUCTION DU STRESS OXYDATIF INDUIT PAR LES STÉROÏDES AVEC DES SUBSTANCES POLYINSATURÉES STABILISÉES
  申请人：RETROTOPE INC

  公开号：WO2015138773A2

  公开（公告）日：2015-09-17

  Some aspects of the invention provide for a method of treating a patient having glaucoma, a non-hereditary optic neuropathy, steroid-induced oxidative stress, or steroid-induced oxidation-related disorders, comprising identifying a patient having a non-hereditary optic neuropathy or steroid-induced oxidative stress or steroid-induced oxidation-related disorders and in need of treatment; repeatedly administering a polyunsaturated substance to the patient or the patient's tissue, wherein the polyunsaturated substance is chemically modified such that one or more bonds is stabilized against oxidation; wherein following said administration, the polyunsaturated substance or a polyunsaturated metabolite thereof comprising said one or more chemical modifications is incorporated into the patient's body or the patient's tissue.